Alien cells may explain COVID-19 brain fog
February 18, 2021
Occlusion of a multitude of tiny vessels by megalokaryocytes may explain the cognitive issues seen in some patients with COVID-19 infection.
ACEIs, ARBs safe to continue in COVID-19: Trial published
January 22, 2021
Recent data suggest that immune dysfunction may contribute to poor outcomes among COVID-19 patients.
COVID-19 anticoagulation trials ‘paused’ for futility, safety
December 22, 2020
The trials involved are the REMAP-CAP, ACTIV-4, and ATTACC studies.
COVID-19 and risk of clotting: ‘Be proactive about prevention’
December 8, 2020
"We believe a systematic way of addressing this risk is best, with every patient hospitalized with COVID-19 receiving some type of thromboprophylaxis," authors of a review article say.
COVID-19 diagnosed on CTA scan in stroke patients
October 29, 2020
“As part of the stroke evaluation workup process, we were able to diagnose COVID-19 at the same time at no extra cost or additional workload.”
COVID-19: Thromboembolic events high despite prophylaxis
October 27, 2020
“Standard prophylaxis as recommended in the guidelines is a low dose of low-molecular-weight heparin once daily, but these results suggest [patients] probably need higher doses.”
First randomized trial reassures on ACEIs, ARBs in COVID-19
September 2, 2020
The BRACE CORONA study found no difference in key outcomes between patients continuing versus stopping their medication.
Captopril questioned for diabetes patients in COVID-19 setting
July 2, 2020
Captopril appears to be associated with a higher rate of pulmonary adverse reactions in patients with diabetes than that of other ACE inhibitors or angiotensin receptor blockers, a new study suggests.
CVD risk continues to fall down to systolic BP of 90 mm HG
June 19, 2020
“From an individual level we can now say that in healthy individuals, a systolic pressure in the 90s is not too low. It is a positive thing.”
COVID-19 neurologic effects: Does the virus directly attack the brain?
June 5, 2020
There are neurologic sequelae of COVID-19. “We need to be alert to these, and to try to understand the potential long-term consequences.”